---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-005486"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2026-01-07T23:59:59+00:00"
generated_at: "2026-05-16T11:23:22.010599+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Adicet Bio reports prula-cel Phase 1 enrollment doubles to 20+ patients; FDA allows outpatient dosing for SLE/LN

## Summary
- Enrollment in prula-cel autoimmune Phase 1 program doubled to over 20 patients as of Dec 31, 2025.
- FDA alignment achieved to allow outpatient dosing of SLE and lupus nephritis patients in ongoing and future trials.
- Plans to request FDA meeting in Q2 2026 to discuss potential Phase 2 pivotal trial design for prula-cel.
- Regulatory filing for ADI-212 in metastatic castration-resistant prostate cancer expected in H1 2026.
- Cash runway extended into H2 2027 following $74.8M net proceeds from October 2025 equity offering.

## SEC filing metadata
- accession: 0001193125-26-005486
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2026-01-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000119312526005486/0001193125-26-005486-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000119312526005486/acet-20260107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-005486
- JSON: https://secwatch.observer/filing/0001193125-26-005486.json
- Plain text: https://secwatch.observer/filing/0001193125-26-005486.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.